Why the study?
Does doxorubicin cause cardiotoxicosis in dogs with malignancies?
Does doxorubicin cause cardiotoxicosis in dogs with malignancies?
Answers are grounded in this paper and cite their sources.
Doxorubicin causes cardiotoxicosis in dogs, including fatal congestive heart failure, though therapeutic benefits may outweigh risks in most cases.
Clinical cardiac abnormalities developed in 32 of 175 dogs that had various malignancies and were treated with doxorubicin: 31 dogs had electrocardiographic abnormalities including arrhythmias and nonspecific alterations in the R wave, ST segment, or QRS duration and 7 dogs had congestive heart failure. All seven dogs that had congestive heart failure died within 90 days. At necropsy, 13 of 32 affected dogs had noninflammatory myocardial degeneration, myocytolysis, vacuolation, and/or fibrosis and there was intramural coronary arteriosclerosis in all 13. Five dogs with lymphosarcoma were in complete clinical remission when they died of doxorubicin-induced cardiomyopathy, but the overall survival times of the lymphosarcoma subset was nevertheless longer than in previous studies. The clinical use of doxorubicin in the dog can cause cardiotoxicosis but the therapeutic benefit appears to outweigh risks in most dogs.
No takes yet. Share an insight, caveat, or question.
Mauldin et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: